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Abstract. The methylation status of a gene promoter is
considered to be an important mechanism for the development
of many tumors, including colorectal cancer. Recent studies
have shown that specific patterns of DNA methylation across
multiple CpG loci in some human tumors are more informative
than the detection of one single CpG locus in tumor genomes.
In the present study, multiple CpG methylations of three genes
(CDKN2A, DPYD and MLH1) were detected in DNA samples
from patients with colorectal cancer using Pyrosequencing®
technology. The bisulfite-converted DNA was amplified with
a nested PCR and five or six CpG loci of each gene were
assessed to determine DNA methylotype. Our data showed that
10/49 (20.4%), 6/48 (12.5%) and 14/49 (28.6%) of tumors were
methylated with a DNA methylation level >0.2 in CDKN2A,
DPYD and MLH1, respectively. Our study indicated a similar
DNA methylation level across the multiple CpG loci for all
three genes in the methylated tumor DNA samples, demon-
strating a dichotomous trait in DNA methylation. The tumor
DNA samples had unique DNA methylation patterns, which
were high-degree and multiple-site methylation, but the normal
DNA samples had no or a low-degree and dispersed single-
site methylation. In addition, an inverse correlation in those
methylated tumors was observed between DNA methylation
and RNA expression for MLH1 (RS=-0.62, P=0.003), but not
for CDKN2A and DPYD. In conclusion, distinctive DNA
methylotypes exist in colorectal cancer and may depict a
distinct biology in apparently homogeneous tumors.
Introduction
The epigenetic silencing of many genes due to CpG island
hypermethylation is considered to be one of the most important
mechanisms for the development of many tumors, including
colorectal cancer (1-3). CpG islands are 0.5- to 2-kb DNA
regions rich in cytosine-guanine dinucleotides and are
present in the promoter region of approximately half of all
human genes. DNA hypermethylation generally leads to a
reduced RNA expression level and hypomethylation gives rise
to active gene transcription (1,2). It is widely reported that
hypermethylation of the DNA mismatch repair gene MLH1
and tumor suppressor gene CDKN2A is frequent in colorectal
cancer and associated with a decreased RNA and protein
expression (1,4,5), but these were described with studies of
one single CpG locus in the gene promoters. In addition, in the
recent studies of dihydropyrimidine dehydrogenase (DPYD),
the initial and rate-limiting enzyme in the catabolism of 5-
fluorouracil and hypermethylation of the DPYD promoter is
associated with DPYD enzyme deficiency in patients with
colorectal cancer (6).
Just as genetic variation across a gene shows distinct
haplotypes, recent studies demonstrated that specific patterns
of DNA methylation across multiple CpG loci (methylotype) in
some human tumors are more informative than the detection
of one single CpG locus in tumor genomes (7-9). For instance,
Yegnasubramanian et al (7) noted that by using various
combinations of several genes such as GSTP1, APC and
ABCB1, the CpG island hypermethylation can distinguish
primary prostate cancer from benign prostate tissue,
demonstrating the tissue-specificity in DNA methylation.
Furthermore, the different CpG loci in the promoter region can
exhibit a different methylation status (8), suggesting that a
multiple CpG investigation in DNA methylation studies is
important (9). This study assessed DNA methylation at
multiple CpG loci and demonstrated the presence of multiple
methylotypes in colorectal cancer.
Materials and methods
Patients and samples. Tumor specimens and paired normal
colon tissues used in this study were from 52 Dukes' C
colorectal cancer patients [29 male/23 female, age range:
32-96 (median 69.5) years], who had not received any
chemotherapeutic agents before surgery. Samples were snap-
frozen in liquid nitrogen immediately after surgery and
stored at -80˚C. The tumor specimens selected for DNA and
RNA isolation had high tumor cellularities. Written informed
consent was obtained from all patients to bank tumor tissue
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and perform genomic analysis. This study was approved by
the Washington University Human Subjects Committee.
Bisulfite conversion of genomic DNA. Genomic DNA was
extracted from the colon tumor and normal tissues using the
Qiagen DNA isolation kit and converted with sodium bisulfite
as previously described (10). After treatment, sodium bisulfite
unmethylated cytosine residues were converted to thymine,
whereas methylated cytosine residues were retained as
cytosine. In addition, a human genomic DNA sample
purchased from Promega (Catalog No. G304A) was included
either as a negative control (unmethylated) when it was
converted only by sodium bisulfite or as a positive control (high
methylation) when it was treated first by the SssI methylase
(New England Biolab, Beverly, MA) and then converted by
sodium bisulfite.
Amplification of the promoter region. A nested PCR approach
was used to amplify the bisulfite-converted DNAs. A scheme
for the methylation assay is shown in Fig. 1. The regular
PCR primers were designed using Primer Express v1.5
(Applied Biosystems, Foster City, CA) and the Pyrosequencing
primers were designed using the single nucleotide poly-
morphism primer design online software at www.biotage.com.
All methylation primers are listed in Table I. The first-round
external PCR reaction was carried out for 40 cycles using an
Amplitaq Gold PCR master mix (Applied Biosystems), 5 pmole
of each primer and 10 ng of the bisulfite-converted genomic
DNA in a 20-μl reaction. The external reaction was run at 94,
55 and 72˚C for 1 min each, while the second-round nested
reaction was run for 55 cycles at 94, 60 and 72˚C for 1 min
each for MLH1 and 30 sec each for CDKN2A and DPYD
amplification. The nested reaction was carried out with 5'-
biotinylated reverse or forward primers in a 20-μl reaction
containing 2 μl of 1:5 diluted first-round PCR products and
4 pmole of each primer.
The Pyrosequencing reaction. Pyrosequencing was performed
as previously described (11) using the Pyrosequencing® PSQ
HS96A instrument and allele quantification software (Pyro-
sequencing, Uppsala, Sweden). The Pyrosequencing reaction
contained 5'-biotinylated single-strand PCR fragments
(purified from 10 μl of the second-round PCR products) and
2.4 pmole Pyrosequencing primers, followed by the
sequential addition of enzymes, substrate and dNTPs. In order
to validate specificity of the Pyrosequencing reaction, negative
controls were set with a fragment only, Pyrosequencing primer
only or no primer and fragment.
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Figure 1. Scheme of DNA methylation assay for CDKN2A, DPYD and MLH1. The dashed arrow denotes the external primers, the one-line arrow denotes the
nested primers, the one-line arrow with a ball denotes the biotinylated primers and the double-line arrow denotes the Pyrosequencing primers.
Table I. Primer list of DNA methylation assay (upper case denotes a transition of C to T or G to A).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Primers (all 5' to 3') CDKN2A DPYD MLH1
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
First round forward gtTTTtTTagaggatttgagggataggg tttagTagtttagagattaaaggTTagt tttTtTaaTtTtgtgggttgTtggg
First round reverse tacctAattccaattcccctAc AAAccatAAcaAtAcctacaAtc AAaAAccacaaAaAcaAAAccaa
Second round forward gTtggTtggtTaTTagagggtgg ggTtgaaTtgggaagg TtgTTcgTtaTTtagaaggatatg
Second round reverse ctAcaAaccctctacccacct aAtctAccaAtAacaaaccctc tctActcctattAActAAatatttc
Pyrosequencing gagggggagagTaggTag ggTtgaaTtgggaagg TcgTtaTTtagaaggatatg
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Determination of the DNA methylation level. By applying the
allele quantification function in the Pyrosequencing system,
the percentage of the C allele in a C to T polymorphism (i.e.,
the DNA methylation level) was determined for each CpG
locus according to a theoretical histogram and peak height
adjustment factor (Fig. 2). An average percentage of the C
allele (i.e., C/T ratio) from three experiments was used for the
DNA methylation status at each CpG locus. For the overall
DNA methylation status of a gene, the mean C/T ratio of all
CpG loci tested for that gene was calculated. When the mean
C/T ratio is <0.05, it is defined as unmethylated (UM).
Otherwise, 0.05-0.20 is denoted as low (LM), 0.21-0.50 as
medium (MM) and >0.50 as high methylation (HM).
Measurement of RNA expression. Real-time quantitative PCR
(qPCR) was employed to the measure relative RNA expression
level of the three genes as previously described (12). Briefly,
a 10-μl reaction mixture for qPCR was composed of 5 μl of
2x TaqMan universal PCR master mix (Applied Biosystems),
3 μl of primer and probe mix (600 nM each forward and
reverse primers, 100 nM specific TaqMan probe) and 2 μl of
cDNA (20 ng). All real-time PCR assays were performed in
triplicate on an ABI Prism 7900HT Sequence Detector
System (Applied Biosystems). An internal reference gene
called amyloid ß precursor protein, which had nearly an
identical expression between colon tumor and normal tissues,
was used to control variation in RNA concentration across
individual samples. Primers and TaqMan® probes used in this
study were designed using the Primer Express version 1.5
(Applied Biosystems) and the qPCR primers and probes are
shown in Table II.
Statistical analysis. Statistical analyses were performed with
the software Statistica (StatSoft, Inc., Tulsa, OK, USA). The
significance of difference of the DNA methylation level
between the multiple CpG loci of each gene was evaluated
ONCOLOGY REPORTS  20:  921-927,  2008 923
Figure 2. A representative Pyrogram for understanding the quantification of the DNA methylation level based on a theoretical histogram and peak height
adjustment factor.
Table II. Primer and probe list of RNA expression assay.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gene symbol Forward primer Reverse primer TaqMan probe
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
CDKN2A CATAGATGCCGCGGAAGGT ATCTAAGTTTCCCGAGGTTTCTCA TCAGACATCCCCGATTGAAAGAACCAGAG
DPYD CTTCAGTTTCTCCATAGTGGTGCTT TTTGAGGCCAGTGCAGTAGTCTT CTCCAGGTATGCAGTGCCATTCAGAATCA
MLH1 CCATCCGGAAGCAGTACATATCT ATGGAGCCAGGCACTTCACT AGGAGTCGACCCTCTCAGGCCAGC
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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by the Kruskal-Wallis median ANOVA test. A correlation
between variables was observed with the Spearman rank
order test. The significance level was set at P<0.05.
Results
Level of DNA methylation. Overall there were 17/49 (34.7%),
19/48 (39.6%) and 20/49 (40.8%) of tumors which were
defined as DNA-methylated (C/T ratio ≥0.05) in CDKN2A,
DPYD and MLH1, respectively. Amongst these methylated
tumors, MM and HM were observed in 9 and 1 tumors (20.4%)
for CDKN2A, 2 and 4 (12.5%) for DPYD and 5 and 9 (28.6%)
for MLH1, respectively.
The dichotomous trait of DNA methylation. The Pyro-
sequencing reactions in this study evaluated 5 or 6 CpG loci
per gene of interest. The degree of methylation at a single CpG
locus in methylated tumors varied from 5.2 to 100%. A similar
degree of DNA methylation was observed across the multiple
CpG loci for each of the 3 genes (P=0.10-0.73, Fig. 3). It
suggests that the DNA methylation of the multiple CpG loci
within a CpG island is a dichotomous event, i.e., either all or
none of the multiple CpG loci were methylated.
Specific pattern of DNA methylation. By analyzing the
methylation level of the multiple CpG loci, five specific
patterns of DNA methylation were apparent: i) unmethylated at
all loci, ii) low methylated at any of the loci, iii) low-medium
methylated at any of the loci, iv) medium-high methylated at
all loci and v) high methylated at all loci. As shown in
Table III, the tumor DNA samples had diverse patterns of
DNA methylation for all three genes in this study. In the highly
methylated tumor DNA samples (types 4 and 5), type 5 was
predominant for MLH1 (8/49, 16.3%), type 4 for CDKN2A
(9/49, 18.4%), but neither type 4 nor 5 for DPYD (8.4 and
2.1%, respectively). However, the normal DNA samples had
only low levels of DNA methylation (types 1 and 2) for all
three genes (Table III). In addition, the 5 methylation types
were each assigned a score of 1, 2, 3, 4 and 5 accordingly and
then a sum score of the 3 genes was given for each tumor
YU et al:  METHYLOTYPE IN COLORECTAL CANCER924
Figure 3. Similar DNA methylation level across the multiple CpG loci of the 3 genes (CDKN2A, DPYD and MLH1).
Table III. DNA methylation patterns of the 3 genes in colorectal cancer.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Type 1 Type 2 Type 3 Type 4 Type 5
(None) (Low) (Low-median) (Median-high) (High)
Tissue Gene ––––––––––––––– –––––––––––––– –––––––––––––– –––––––––––––– ––––––––––––––
n Mean n Mean n Mean n Mean n Mean
methylation methylation methylation methylation methylation
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Tumor CDKN2A 17 0 16 0.03 7 0.17 9 0.34 0 0
DPYD 15 0 21 0.05 7 0.18 4 0.58 1 0.86
MLH1 18 0 16 0.04 4 0.25 3 0.47 8 0.81
Normal CDKN2A 28 0 20 0.03 0 0 0 0 0 0
DPYD 22 0 25 0.08 0 0 0 0 0 0
MLH1 34 0 14 0.05 0 0 0 0 0 0
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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(DNA methylotype). The distribution of the tumor DNA
methylotype (Fig. 4) showed that the majority of the tumors
had methylotypes with no or a low level of DNA methylation
(sum score 3-8: 37/45, 82%) and 18% of tumors were median-
highly methylated (sum score 9-13: 8/45).
Correlation of DNA methylation with RNA expression. The
tumor RNA expression was significantly correlated inversely
with the average DNA methylation level for MLH1 (RS=-0.62,
P=0.003) but not for CDKN2A and DPYD (RS=0.17 and 0.36
and P=0.52 and 0.13, respectively) in those methylated tumors.
The MLH1 and DPYD methylation data were previously
described in brief within published articles (13,14).
Discussion
As more comprehensive and quantitative methods in
assessing DNA methylation emerge, it has been suggested that
epigenetics will play a more important role in understanding
the development and progression of human diseases such as
cancer (15-18). A rapid, accurate screening technique is
essential in assessing DNA methylation in multiple CpG sites
(9). Below we discuss some of the technical aspects of
Pyrosequencing in the application of DNA methylation
assessment in conjunction with the results of this study.
Many of the previous DNA methylation studies were
conducted at a single CpG site, which gave no information for
DNA methylation patterns of gene promoter regions. On the
other hand, although global genomic DNA methylation content
(proportion of 5-methylcytosine in the entire genomic bases)
may have an important role in carcinogenesis, its measurement
in cancer cells has little to offer as a molecular marker, either
in sensitivity or informational content (9,19). In contrast, the
DNA methylation pattern/methylotype, built upon the
measurement of multiple CpG methylation, can provide
detailed information on the characterizations of the 5-
methylcytosine distribution along a stretch of DNA, thereby
providing a unique approach to genome-wide molecular
profiling (9,20,21). In the present study, we have defined 5
different types of DNA methylation patterns with multiple
CpG loci for those three genes. Notably, the tumor DNA
samples have distinctive methylation patterns from the normal
DNA samples; i.e., for the methylated DNAs, the tumor
samples are characterized by multiple-site and high-degree
CpG methylation and the normal samples are characterized
by a dispersed single-site and low-degree CpG methylation
(Table III), suggesting the importance of the DNA methylation
pattern as a potential marker in molecular diagnostics. In
addition, the tumor DNA methylotype has the potential to
identify patient groups with either high or low methylation
according to the dichotomous trait of the DNA methylation
within the CpG islands. However, in the distribution of the
tumor DNA methylotype our data did not clearly display the
two patient groups: high and low methylation groups. Instead
it showed a continuous distribution of the tumor DNA
methylotype across the spectrum of possible configurations.
Further studies with a larger number of genes are needed to
clarify the importance of tumor DNA methylotype in
identifying patient groups based on the DNA methylation
patterns.
Pyrosequencing can also generate quantitative data for the
DNA methylation level (21). However, the concept of the
DNA methylation level can be confused in the literature,
because this level may be representing either how many
molecules with a gene sequence of interest in a DNA sample
or how many CpG loci in a gene sequence for a certain DNA
sample have been methylated. The C/T ratio in this study
served as the DNA methylation level for a given gene,
meaning how many molecules with a gene sequence of
interest in a DNA sample have been methylated. However,
the Pyrosequencing protocol used in this study also presents
how many CpG loci have been methylated in a single reaction.
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Figure 4. Distribution of the tumor methylotype based on the DNA methylation patterns of the 3 genes (CDKN2A, DPYD and MLH1).
921-927  12/9/08  15:52  Page 925
Therefore, when we assess a gene for hypermethylation, it is
better to describe the DNA methylation level in at least two
dimensions: how many molecules in a DNA sample and how
many CpG loci in a gene sequence have been methylated. Most
DNA samples from tissue specimens have mixed genomes
from a variety of cell-types including cells not of interest to
the study (e.g., stromal cells) and different cells or tissues that
can be methylated differentially at a specific CpG locus. The
DNA mixture from different types of cells can mask the true
level of DNA methylation at a specific CpG site for a specific
type of cell. This is particularly important for quantitative DNA
methylation studies and laser capture microdissection, while
fluorescence-activated cell-sorting can provide highly pure
cells of specific types.
Moreover, the detection potential of multiple CpG loci
with Pyrosequencing allows the comparison of differential
levels of DNA methylation between multiple CpG loci. As a
result, a similar DNA methylation level is found in our study
at multiple CpG loci for all three genes in the methylated
tumor DNA samples; i.e., a tumor DNA sample either has no
methylation for a single CpG locus or has a similar methylation
level across the multiple CpG loci in the tumors. It suggests
that DNA methylation is a dichotomous event. Taken together
the dichotomous traits and specific patterns identified by
Pyrosequencing and DNA methylation in cancer cells can be
differentiated from that in normal cells both qualitatively
and quantitatively. However, Pyrosequencing has several
disadvantages (15,21). First of all, it has a reading length limit
in a single reaction (currently less than 75 bp and 10 CpG loci)
and cannot be used to detect an entire CpG island. Due to
difficulties in primer design, it cannot always be used to detect
certain regions in a CpG island. Moreover, it cannot be used to
detect a specific haplotypic pattern of DNA methylation
because it utilizes double-stranded templates.
In addition, our study demonstrates an inverse correlation
between DNA methylation and RNA expression for MLH1.
It is notable that the region of the gene promoter detected for
MLH1 methylation in our study is indicated in a previous
study (22) showing that the methylation status invariably
correlates with the lack of MLH1 expression (-248 to -178,
relative to the transcriptional start site). But for CDKN2A and
DPYD in our study, the RNA level is not associated with the
DNA methylation level in the promoter region indicated in
Fig. 1. It has been noted that the CpG island of the CDKN2A
promoter extends to exon 1 and 2 and the hypermethylation
of CDKN2A exon 2 is accompanied by an increased but not
decreased expression via a so-called transcriptional-coupled
methylation (5). Our results do not indicate a correlation
between the DNA methylation level and RNA expression but
indicate a positive methylation-expression correlation for
CDKN2A even though it does not reach a statistically
significant level of correlation. Meanwhile, we have noted a
recent study (23) showing two transcriptional regulatory
elements close to the transcription start site (-72 to -23) of
DPYD. The CpG loci in DPYD detected in our study (-119 to -
86) do not locate in either binding site of the two
transcriptional regulatory elements. Our results indicate that
the CpG loci of DPYD tested in our study do not hold the
potential to regulate the RNA expression. Even though further
studies are needed to define the relationship between the
DNA methylation and RNA level for CDKN2A and DPYD,
our study otherwise suggests that the specific patterns and
locations of DNA methylation as well as the tissue-specific
methylation can be more important in cancer epigenetics. As
such, DNA methylation in the promoter regions has a
substantial effect on gene transcription but not in the coding
region (19).
In conclusion, our data suggest that distinctive DNA
methylotypes exist in colorectal cancer and may depict a
distinct biology in apparently homogeneous tumors.
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